An Open Label, Phase Ib Study to Evaluate the Impact of Low Doses of Nilotinib Treatment on Safety, Tolerability and Biomarkers in Huntington's Disease An Open Label, Phase Ib Study to Evaluate the Impact of Low Doses of NilotinibTreatment on Safety, T ...